Andy Moreo

Nov 19, 2024 | outsourcedpharma.com | Louis Garguilo |Alex Klarer |Cory Lewis |Andy Moreo

As the pipeline of viral vector-based therapies continues to reach later stage studies, a standardized manufacturing process is necessary for chemistry, manufacturing, & control (CMC) requirements from regulatory agencies. Several of the challenges to standardize viral vector manufacturing include bottlenecks in the supply chain, lack of scalability in processes, and variability associated with customer-driven SOPs. Click here to learn more about Catalent’s UpTempoâ„  AAV platform solution.